Ved International Journal of Arts, Commerce and Technology (VIJACT)
© VIJACT |Vol.2, Issue3, March 2026, pp. 01-21 | ISSN: 3139-1656 (Online)
DOI: https://doi.org/10.65785/vijact.v1i3.20
Available online at: https://vijact.com/

BIOINFORMATICS AND INTELLECTUAL PROPERTY PROTECTION: AN OVERVIEW

Dr. Manindra Singh Hanspal

Article Info

Article history:

Received Mar 11, 2026

Accepted Mar 17, 2026

Published Mar 31, 2026

Keywords:

Sustainable ICT

Remote and Hybrid Learning

Educational Technology

ICT Infrastructure

ABSTRACT

An interdisciplinary field at the interface of biology, computer science and information technology, bioinformatics has become a key area of research in furthering biological research, especially genomics, proteomics and data-based medical findings. With the expansion of bioinformatics, there is a corresponding increase in the need to have proper intellectual property (IP) protection to protect innovation, stimulate investment and promote collaborative research. This paper examines the intricate environment surrounding IP protection in bioinformatics and the significance of IP in ensuring a competitive advantage and in motivating additional advancement in this fast moving discipline. The main aims of the study are to review available IP models in bioinformatics, determine key issues in patenting of biological data and software algorithms, and suggest specific suggestions to enhance IP protection in the area. The employed methodology consists of a doctrinal analysis, which involves legal doctrine and regulations, and comparing the approaches to IP in various jurisdictions to demonstrate successful practices and areas that require reform. The major conclusions are based on the fact that the existing IP legislations do provide certain protection to bioinformatics breakthroughs, however, there are still significant gaps, especially in the field of ownership of the data, licensing and patentability of algorithms. The absence of the homogeneity of the IP regulations in various territories makes the process of protection even more complicated, which may impede the international cooperation. The paper ends with the emphasis on the necessity of a flexible and strong IP framework that is responsive to the specific needs of bioinformatics and would allow the latter to flourish without violating any ethical considerations or facilitating the accessibility. Overall, the proposed study highlights the urgency of creating IP protection strategies that will address the specific requirements of bioinformatics and ensure the balance between innovation and ethical implications in the use and availability of biological data.

Corresponding Author:
Dr. Manindra Singh Hanspal
Assistant Professor, Presidency University, Bengaluru, Karnataka
Email: mhanspal21@gmail.com

1. INTRODUCTION:

1.1. Background and Context

Bioinformatics is an interdisciplinary science, a branch of computer science and biology that combines computer science, biology, and information technology to analyze, examine, and interpret intricate biological data. It is mainly the application of computational tools and computational methods to handle and analyze big data, especially in genomics, proteomics, and molecular biology [1]. Owing to the present-day methods of DNA sequencing, mass spectrometry, and other high-throughput methods, bioinformatics is now required in dealing with the large volumes of biological data [2]. Bioinformatics plays a central role in revealing the information that cannot be obtained through the traditional methods of biological research, enabling scientists be able to obtain meaningful interpretations of large volumes of biological data. In modern times, bioinformatics is also part and parcel of several fields in the fields of genomics, proteomics, and personalized medicine. Bioinformatics tools in the field of genomics are also able to assemble, annotate and compare genomes of various organisms and provide information about the structure and functionality of genes [3]. This has been found especially in the case of studying complex diseases like cancer, diabetes and cardiovascular diseases, where bioinformatics can be used to find biomarkers of diagnosis and possible therapeutic targets [4]. In biotechnology, bioinformatics assists in developing genetically engineered organisms to be used in agriculture, to produce biofuel, and to manage the environment and in this case, scientists are able to design organisms with certain advantageous characteristics [5].

1.2. Importance of Bioinformatics in Modern Research

The advances that have been brought about by bioinformatics have revolutionized the healthcare and biological research fields. The Human Genome Project (HGP) is one of the most prominent contributions that is considered a historic bioinformatics project that has concluded the sequencing of the complete human genome. According to Venter et al. (2001), this has been a very valuable point of reference in the study of human genetics and has created new avenues in the diagnosis of genetic diseases and therapy. The tools and methodologies that were created in the course of the HGP have since become fundamental in the discipline, enabling the creation of progress in cancer genomics, where scientists apply bioinformatics to determine genetic mutations that are linked to cancer as well as forecasting the responsiveness of patients to particular treatments [6].

Bioinformatics has resulted in the creation of diagnostic tools and strategies of personalized medicine, which enhance patient outcomes in health care. As an example, bioinformatics algorithms can be used to determine the likelihood of a disease by examining the genetic makeup of a patient, including hereditary breast and ovarian cancer, which are caused by the mutation of BRCA1 and BRCA2 genes [7]. Such insights allow healthcare providers to prevent or adopt intervention plans or select treatments that have higher chances of being effective in particular genetic profiles. This has been increasingly becoming popular under the umbrella of precision medicine [8]. Also, bioinformatics can help in identifying molecular disease markers, like a particular protein or even gene activity, that can be used as a diagnostic indicator or a disease prognosis indicator [9]. The field of bioinformatics is still driving the future of biotechnology by allowing the engineering of organisms to be used in a certain application. By way of illustration, bioinformatics instruments develop artificial genes which can be implanted in plants or microorganisms to generate biofuels, enzymes, or drugs by scientists [10]. Furthermore, in the biotechnology of agriculture, bioinformatics can be used to help identify genetic characteristics of high yield, resistance to disease or environmental stress, and thus it can be applied in the creation of genetically modified crops to overcome food security problems [11].

These assistances highlight the transformational nature of bioinformatics in healthcare and research in the biological field. Nonetheless, the further bioinformatics technology will be developed, the more the legal structure is required to safeguard the intellectual property (IP) created in the field. It is common in present IP laws to be out of step with the realities of bioinformatics, where algorithms, databases, and proprietary genetic data are the focus of protection, and each of them constitutes a special problem. These issues must be resolved to promote bioinformatics innovation and enable researchers and developers to secure their intellectual property.

1.3. Overview of Intellectual Property (IP) Laws Relevant to Bioinformatics

Intellectual Property Rights (IPR) are the legal provisions that are given to creators and inventors of their creations, inventions and intellectual work. The rights are aimed at providing creators with the opportunity to have exclusive rights on the use of their works, production, and distribution to protect their innovations, receive financial profits, and eliminate illegal use of the work by other individuals. The intellectual property rights have a number of types like patents, copyrights, trademarks and trade secrets, which are used to safeguard certain forms of scholarly work.

- **Patents:** Inventions or discoveries are protected that offer a new way of doing something or provide a new technical solution to a problem.
- **Copyrights:** Literary works, artistic works like software code, publications and databases, as well as other works, are subject to copyright, and their creators have the exclusive right to reproduce and distribute the work.
- **Trademarks:** The trademarks are used to secure unique signs or symbols that are used in identifying goods and services.
- **Trade Secrets:** Secrecy of trade secrets Protect trade secrets, such as formulas, practices, or designs, that confer a competitive advantage.

All these rights are known to create an environment of innovation because they provide assurance to individuals and businesses that they can make a profit out of their intellectual property without the worry of being stolen [12].

Relevant to Bioinformatics

Patents give their inventors exclusive rights to their inventions, usually at the expense of displaying the workings publicly. In bioinformatics, novel algorithms, software applications and data-processing methods created to analyze biological data can be patented by researchers [13]. The fact that the field requires huge datasets and specialized computational techniques makes it crucial that the creators protect their intellectual property rights to preserve a competitive advantage and stimulate investment.

- **Bioinformatics Tools:** Bioinformatics is based on advanced software to perform sequence alignment, gene prediction and structural analysis. Securing these tools by IPR guarantees developers to have exclusive rights to their original algorithm and methods, the replication and alteration of which cannot be repeated.

- **Biological Databases:** Bioinformatics studies frequently include the development of massive biological databases, which assemble genetic, protein and metabolic knowledge. Copyrights enable the creators of databases to keep control, license their database, and ensure the integrity of their data, which encourages further research and development [14].
- **Algorithms:** Bioinformatics algorithms are necessary in making sense out of biological data. Because the algorithms can be patented, the patents on such innovations prevent their imitation, promoting research, and securing creators the rights to their innovations [15].

Table 1: Types of Intellectual Property in Bioinformatics

Type of IPR	Bioinformatics Application	Purpose
Patents	Bioinformatics algorithms, novel data analysis techniques	Protects unique inventions and methods
Copyrights	Databases, software code, research publications	Prevents unauthorized copying or use
Trademarks	Software tools and service branding	Distinguishes products and services
Trade Secrets	Proprietary algorithms, data processing techniques	Keeps a competitive edge with confidentiality

Here, the table emphasizes that the various types of IP are used differently in bioinformatics, as each type offers specific protection to encourage innovation and safeguard proprietary rights.

1.4. Statement of the Problem

The traditional intellectual property (IP) laws, when applied to bioinformatics, have a number of challenges owing to the specificity of bioinformatics innovations. Conventional IP systems were developed around physical inventions and unambiguous works of authorship. However, bioinformatics frequently entails difficult-to-define and intangible properties, such as algorithms, genetic information, and software, that cannot be easily categorized as IP. Some of the major challenges are patenting bioinformatics algorithms, ownership/sharing of data, and international IP rights disputes, especially where there is an international collaboration in the course of the research. Moreover, the problem of ethical implications of privacy information and commercialization of genetic information makes it difficult to apply traditional IP laws in this new area.

1.5. Research Objectives

- To determine the effectiveness of the existing intellectual property regulations in ensuring innovations in bioinformatics.
- To explore the international legal systems touching on bioinformatics and its effects on IP protection.
- To find out major legal and ethical concerns in the protection of bioinformatics in the intellectual property law.
- To provide viable recommendations on how to enhance intellectual property protection regarding bioinformatics developments.

1.6. Research Methodology

The study uses a doctrinal legal methodology, which is the analysis of statutes, case laws and principles of bioinformatics IP protection. The national and international IP laws and judicial decisions are the primary sources, whereas the secondary sources consist of scholarly articles and expert commentaries. Comparative jurisdictional analysis can determine gaps, inconsistencies and best practices, which offer a cross-border view on IP protection. This approach will be used to evaluate existing paradigms and point to possible improvements in bioinformatics IP.

2. LITERATURE REVIEW:

The purpose of this literature review is to examine and summarize scholarly literature that covers the present situation in intellectual property (IP) law in terms of bioinformatics. In particular, this section will look at the difficulties encountered in the protection of IP over software, algorithms and databases, all of which are the basic pillars in bioinformatics.

Cohen and Lemley (2001) discuss the challenges in the enforcement of algorithmic patents, especially in software and bioinformatics. According to them, the flexibility of software allows competitors to develop a functional equivalent that will avoid patent protection, which results in a patent thicket. Such overlap of many patents is counterproductive to innovation and results in high litigation costs, and it is important to note that narrower and more specific patent claims are necessary [16]. Derclaye (2008) discusses the vulnerability of the copyright law to safeguard the bioinformatics databases, where it only ensures the data is safeguarded in its arrangement, not in its contents. She emphasizes the sui generis approach of the European Union Database Directive, which offers a stronger protection of the databases in Europe. She, however, mentions the non-existence of similar protections in other jurisdictions like the United States, where trade secrets are usually the only available option [17].

Gopalan (2009) focuses on the combination of intellectual property (IP) protection and bioinformatics and discusses the basic mechanisms, including patents, copyright, and trade secrets. The paper identifies the two-sided nature of IP as a driver of innovation and a source of ethical issues and the possible impairment of information exchange and cooperation among scientists. Nevertheless, the scope of the paper can restrict its applicability because the study concentrates on the legal frameworks of 2009, which can be applied only to the current practices and developments in the field of bioinformatics [18]. The paper by Bagley (2014) addresses the issue of patenting eligibility, especially when it comes to such emerging technologies as bioinformatics. She explains why, according to the current laws, it is intrinsically hard to classify bioinformatics algorithms and software as patentable subject matter and tends to refer to them as abstract ideas. Bagley notes that more specific legal frameworks are needed to promote innovation and solve the specificities of bioinformatics technologies [19].

The article by Singh and Singh (2015) discusses the interplay of intellectual property (IP) protection and bioinformatics, with genomic databases in the spotlight. They also make analogies to the open-source biotechnology practices, arguing that it is necessary to follow the middle way to allow innovation and keep access to the important data. The authors suggest the compatibility of the open-source paradigms and conventional IP models. Nevertheless, their use of analogies can reduce the complexity of IP protection and fail to address certain legal issues that researchers face when conducting research in the field [20]. Atsar (2017) explores bioinformatics inventions in Indonesia and Singapore and evaluates the shortcomings and advantages of the intellectual property systems in both countries. The research also uncovers the deficiencies in the legal protection, wherein Singapore has a better system, but Indonesia has difficulty with enforcement and IPR awareness. Nonetheless, the analysis of two countries might not be the most useful to generalize findings, and the changed bioinformatics sphere might not be considered in its entirety [21]. Kumar (2019) explores the complexities of intellectual property protection for bioinformatics innovations, focusing on the criteria for patentability, such as novelty and non-obviousness. In his article, Kumar

(2019) discusses the nuances of safeguarding bioinformatics innovations under the intellectual property protection laws and includes the criteria of patentability, including novelty and non-obviousness. The paper has also indicated the challenges encountered by the researchers in maneuvering the patent system, especially of software and algorithms in bioinformatics. Its focus on patentability, however, might overlook other applicable types of IPR, including copyrights and trade secrets, and does not give a detailed examination of the IPR situation in bioinformatics worldwide [22].

Egbunike (2021) investigates the issue of human patents by exploring how people have the right to their genetic material and the implications of biosecurity in general. The paper identifies ethical and legal concerns surrounding the issue of patenting human genes, and proposes stricter control of the problem, which would safeguard the rights of every individual, and the consequences of such a choice in regard to global health security. Although this is a credible discussion, the analysis might not be deep enough as it does not dwell in depth on the existing legal precedents on human patents and only provides a theoretical discussion on biosecurity without case studies or previous incidents to put it in context [23]. The paper authored by Nath and Chakravarty (2023) examines the emerging intellectual property rights (IPR) in the area of human genomics in India and highlights the relationship between the law, innovation, and societal health. They recommend a stronger IPR framework that will accommodate the interests of the stakeholders, such as researchers, corporations and the populace and handle the ethical concerns as far as genetic information is concerned. The scope of the study is, however, restricted by the fact that it researched on India alone, and the study may not exhaust the clash between IPR and moral issues [24]. Patel et al. (2023) discuss the ethical issues in the process of implementing artificial intelligence (AI) in bioinformatics and cheminformatics. They raise the issues of privacy of the data, informed consent, and the bias of the algorithms and state that ethical regulations should be applied to make the areas of such activity just and safe. Although the theoretical background of the chapter is useful, there is no empirical evidence and real-life case studies, and this fact restricts the implementation of the chapter in the real-life regulatory and industry practices [25].

Gomase, Kemkar, and Potnis (2024) examine the Intellectual Property Rights (IPR) system in India that is currently conducive to the commercialization of biotechnological innovations, including seed improvements, monoculture, and patenting of new plant varieties, microorganisms, and genetically modified organisms. Although this framework has brought biotechnology to the fore, there is also the concern of depletion of the rich biogenetic diversity in India. According to the authors, there should be a middle ground, which should be a harmonization of the official IPR structures and sustainable biodiversity objectives. Most of the biotechnology programs in India are supervised by the Department of Biotechnology, which is under the Ministry of Science and Technology and which aims at enhancing research, infrastructural advancement, human resources development and ensuring biotechnology industries promotion. Moreover, the Department also implements biosafety regulations of the genetically modified organisms and recombinant DNA products, in order to serve the interests of society, in addition to establishing a strong bioinformatics network which connects the scientific mission of India to all other parts of the world [26].

Alice Corp. Vs. CLS Bank International and Patent Eligibility. The case of Alice Corp. v. CLS Bank International, 573 U.S. 208 (2014), by the Supreme Court reinterpreted the eligibility of patents under 35 U.S.C. § 101 and concentrated on the claims that concern abstract concepts. The patents of Alice Corporation to settle the settlement risk by using a computer-based system were not eligible. They entailed a basic economic procedure lacking an innovative idea to bring the abstract concept to a patentable invention. The Court decided that generic computer implementations, like computerization of shadow accounts and balance adjustments, are amenable to efficiency enhancement, but do not qualify as patentable under the requirements of the latter assessment, unless they enhance computer functionality or technology. This historic case showed the restriction of patenting abstract ideas, and it affected such domains as software and bioinformatics and created an issue of understanding the laws [27].

The ruling in Mayo Collaborative Services v. Prometheus Laboratories, Inc., 566 U.S. 66 (2012) by the Supreme Court dealt with the issue of patentability of natural laws-based processes. The case was about claims on methods that assist the doctors to optimize the dosages of thiopurine drugs on patients of autoimmune diseases by measuring certain metabolites in the blood. The Court held that the claims did not change the natural laws but only applied them to new applications to make them patentable since the processes were ordinary and normal as were known to scientists. The ruling highlighted the danger of providing patents that will have a disproportionate impact on the application of the basic scientific principles, which can hinder the next discoveries. This case was a landmark decision that reaffirmed the idea that natural laws and their traditional uses are not patentable, having a major impact on the biotechnology and medical diagnostic sector [28]. Diamond v. Diehr (1981) [29], this case of the U.S. Supreme Court has set a precedent regarding patenting inventions related to software. The Court ruled that it was possible to patent an algorithm in case it consisted of a larger industrial process that changed or created a physical outcome. The implication of this decision on bioinformatics was that there are possibilities of patenting software innovations that lead to a tangible technical application.

Association for Molecular Pathology v. Myriad Genetics (2013) [30]: The case of Association for Molecular Pathology vs. Myriad Genetics (2013) decided that naturally occurring DNA sequences cannot be patented as they are naturally occurring products. The Court, however, permitted the patenting of cDNA, which could not be obtained naturally and the ones obtained were created in the laboratory. This ruling has had far reaching consequences on bioinformatics as it restricts the possibilities of companies patenting natural occurring sequences of genes, but it still provides protection against synthetic DNA. This difference is especially applicable in bioinformatics, where genetic information is commonly being applied in computational models and studies.

Gaps in Literature

Although great strides have been achieved in the intellectual property (IP) landscape of bioinformatics, there are still numerous areas in which the topic has not been thoroughly explored or discussed in the literature. Although the use of conventional IP laws in bioinformatics has been studied in the past, this area of study has several specific issues that need special analysis. The main gaps that can be identified are insufficient advice on patenting any bioinformatics-specific algorithm, a lack of sufficient exploration of the protection of biological databases, and a lack of dynamic IP models that can be modified to fit the fast pace of technology. Also, the ethical aspects of the ownership of data, the cross-border IP, and the conflict between open access and the protection of IP are not addressed in detail. These gaps are outlined in the table below, with particular areas marked where more research is necessary to create a more responsive and inclusive IP framework of bioinformatics.

2.1. Comparative International Perspectives

Different countries have adopted various approaches to address the unique IP challenges in bioinformatics, with varying levels of success. While there are some commonalities in IP frameworks across jurisdictions, specific policies and interpretations of IP laws lead to significant differences in the level of protection available for bioinformatics innovations.

IP Approaches in the United States

In the United States, bioinformatics innovations face considerable challenges in securing IP protection. The U.S. Patent and Trademark Office (USPTO) has adopted a restrictive approach to software and algorithm patents, especially following the Alice decision. This ruling established a precedent that software patents must demonstrate a technical improvement beyond abstract ideas to qualify for protection. Consequently, many bioinformatics algorithms and data-processing methods are deemed unpatentable due to their mathematical nature (Kim, 2016). Additionally, the U.S. lacks a sui generis database protection law, which limits protection for bioinformatics databases; instead, database owners rely on copyright and trade secret laws (Samuelson, 2009).

IP Approaches in the European Union

A better environment in which bioinformatics IP protection can be offered by the European Union (EU) is through the introduction of the Database Directive, which grants sui generis rights to the creators of databases [31]. EU Database Directive enables those who own databases to safeguard the effort spent in assembling the data by offering them special privileges in removing and re-using of database information, although the data may not be original. This method is particularly useful in bioinformatics, in which scientists have spent vast amounts of resources on curation of large biological datasets. Software patents are also permitted by the European Patent Office (EPO) provided they help to solve a technical problem, but this can still lock out many bioinformatics algorithms.

IP Approaches in Japan

The approach of Japan towards bioinformatics IP is middle-ground, between the U.S. and the EU models. The Japanese patent law permits the patenting of an algorithm but not on an industrial application. The algorithms of bioinformatics that are created with the purpose of research are not eligible, whereas the ones that are incorporated into medical or industrial practice are more likely to receive a patent [32]. Japan has no particular database protection directive as the EU, so bioinformatics databases can be easily stolen and reused.

Table 3: Patent Eligibility Criteria for Bioinformatics Innovations Across Jurisdictions

Country/Region	Patent Eligibility	Applicable Laws/Guidelines	Limitations
United States	Algorithms in biotech, medical data	USPTO Guidelines for Bioinformatics	Limited by software eligibility criteria
European Union	Software that solves technical problems	EPO Guidelines on Biotech Patents	High threshold for technical contribution
Japan	Database-related inventions	JPO Biotechnology Patent Guide	Limited to industrial applications
Country/Region	Patent Eligibility	Applicable Laws/Guidelines	Limitations

The comparative analysis brings out that there are still major gaps as the different regions manage bioinformatics IP gaps to a certain degree. Strict requirements of patent eligibility are enforced by the United States, restricting bioinformatics algorithms and databases protection and do not provide any specific protection to databases, leaving the datasets vulnerable to misuse. However, on the contrary, the Database Directive of the European Union provides strong safeguarding of bioinformatics databases, but patent eligibility is also a challenge. Japan also offers less protection to patents and they are eligible only on industrial applications, and has no sui generis database rights, like the U.S. These variations serve to point to the necessity of a more harmonized approach to the world or changes to each jurisdiction IP framework in order to safeguard bioinformatics innovations appropriately. With the development of bioinformatics, jurisdictions might have to reconsider and broaden IP protection to facilitate innovation and ensure economic rewards for bioinformatics firms and scientists.

3. ANALYSIS/DISCUSSION

3.1. Understanding Bioinformatics

Bioinformatics is an interdisciplinary science, the confluence of biological sciences, computer science and information technology, to analyze and interpret complex biological data. It mainly comprises the creation of algorithms, software applications, and databases to process, store and manipulate large datasets generated in life sciences, and most prominently, genomics and proteomics. The discipline involves various elements such as computational biology, data mining and statistical analysis to extract meaningful information out of biological data. A subfield of bioinformatics is computational biology, which is concerned with the application of mathematical models and simulations in the study of biological systems. By contrast, data analysis entails a number of methods of handling raw data on biological experiments in order to obtain interpretable outcomes, including genetic sequencing or protein folding [33].

Applications:

Genomics and Proteomics

Bioinformatics plays a role in genomics; sequencing genomes, or finding the entire DNA sequence of the genome of an organism. This is vital in determining the functions of genes, genetic variation and evolutionary relationships among organisms. Basic Local Alignment Search Tool (BLAST) and genome assembly computer programs are common in genomic studies to match genetic sequences and assemble raw data obtained in sequencing machines. Bioinformatics is vital in the study of protein structures and functions in proteomics, which helps the researcher in interpreting the intricate processes of interactions that facilitate the operation of the cell. As an illustration, the prediction of protein structure applications, including AlphaFold, has changed the nature of proteomics by providing high-quality 3D protein structures that can be useful in understanding the mechanisms of diseases [34].

Drug Discovery

In contemporary drug discovery, bioinformatics plays a central role in assisting in the identification of potential drug targets, including particular proteins or genes linked to the disease. Computational tools are used by researchers to filter through large libraries of compounds, simulate drug-target interactions and determine the efficacy and safety of possible therapies. Drug discovery is faster through techniques, such as molecular docking and virtual screening, which enable scientists to screen many compounds using computers before spending large sums of money to conduct experiments in the laboratory [35]. Moreover, bioinformatics aids in genomic data analysis to detect biomarkers, biological predictors of disease or drug response, and this would allow the creation of targeted therapies [36].

Personalized Medicine

Precision medicine or personalized medicine is meant to focus on individual patients, and using their genetic makeup, the treatments are customized so that they are more effective and can cause fewer side effects. The core of this approach is bioinformatics, which allows the analysis of the genomic data of an individual in order to determine genetic variants that can be linked to the response to the drug, predisposition to the disease, or the ability to metabolize drugs. An example is pharmacogenomics, a branch of bioinformatics, which examines the impact of genes on the response of a person to drugs. This knowledge can subsequently be utilized to tailor treatment regimens, including changing the doses of specific drugs or the choice of alternative therapies, depending on the genetic composition of a specific patient [37]. The use of personalized medicine is also on the rise in the field of oncology, where genomic data on tumours is provided to be able to detect mutations that can be targeted by specific drugs [38].

Innovation Drivers

Bioinformatics is a valuable source of innovation, which allows for making discoveries and technological improvements in different domains. Bioinformatics has enabled the discovery of new technologies, including the high-throughput sequencing technologies that enable researchers to sequence entire genomes within hours by combining computational power and biology research. Bioinformatics is used in the development of technologies such as CRISPR gene editing, in which technology developers use the tools to recognize the sequence of a gene and construct the appropriate genetic alteration. Besides, bioinformatics also leads to the creation of synthetic biology in which scientists design biological systems that can be applied to practice, such as the production of biofuels or the creation of artificial organisms [39]. These discoveries enhance our knowledge of life at the molecular scale and offer some viable solutions in medicine, agriculture, and the environmental field.

3.2. Overview of IP Challenges in Bioinformatics

Bioinformatics, based on algorithms, big data and collective research, poses special challenges to the traditional IP frameworks. Originally created to deal with the more tangible and discrete inventions, these frameworks find it difficult to secure the many-faceted and intangible innovations of bioinformatics. Some of the most important IP concerns in bioinformatics are the patentability of algorithms, the constraints of the copyright protection of genetic data, and the challenges of the application of trade secrets in the data-sharing context.

3.2.1. Patent Law and Bioinformatics

The traditional patent laws safeguard inventions that are novel and non-obvious and can be applied in a particular industrial situation. Non-obviousness and novelty are, however, difficult to satisfy the criteria of bioinformatics inventions because of the field. Since bioinformatics is mainly a field that depends on algorithms and calculation operations, the issue of industrial application is also problematic when the practical usefulness of these inventions is not in physical processes or equipment but in data interpretation [22].

Patent Eligibility Criteria

The novelty and non-obviousness criteria of the patent law pose certain difficulties to bioinformatics [40]. Because bioinformatics is sometimes associated with the use of established methods of computation with biological data, patent examiners could, in any case, consider such use to be an obvious application of the methods in the biological sciences even though it was novel in that application [41]. This is also complicated by the fact that bioinformatics is an interdisciplinary field because what might seem self-evident in a computer science field might be considered revolutionary when used in the fields of genetics or proteomics. In the U.S., the Mayo Collaborative Services v. Prometheus Laboratories case made the eligibility of patents even more complicated by holding that natural phenomena, abstract ideas, although put into practical use, cannot be patented when they are based on traditional steps [42]. The case has an impact on bioinformatics innovations that engage in the analysis of biological processes or genetic information in general, since the application can be associated with natural biological processes, which cannot be patented according to the natural phenomenon exception [43].

Jurisdictional Variations and Bioinformatics Patents

The European Union and Japan have followed a patent framework which is to some extent, more flexible to bioinformatics as compared to the U.S. An example is the European Patent Office (EPO), where patents on computer-implemented inventions, such as bioinformatics algorithms, are permitted to make a technical contribution other than data analysis [44]. This is a looser criterion than the one used in the United States, permitting bioinformatics patents to be made on algorithms proving a concrete technical impact, when the ultimate product is the interpretation of data. However, this is not a criterion that most bioinformatics algorithms have, since they do not directly provide physical outputs or transformations. The Japanese award algorithm patents in the same way; however, they require an attachment to an industrial application, e.g., a medical diagnostic [45]. This strategy limits the ability to patent an algorithm, which is de facto only applicable in academic research or theoretical analysis, and helps to protect bioinformatics tools that have no direct applications in industry.

Limitations and Consequences of Patent Exclusions

The inhibitory patent environment of bioinformatics has serious consequences for innovation in the sector. Lacking the option to patent the fundamental algorithms and data-processing techniques, bioinformatics firms might have fewer incentives to invest in research and development because their own proprietary advances are liable to copying by competitors [46]. Besides, the exorbitant expenses of protecting trade secrets or copyright of bioinformatics databases and software, in addition to the inability to patent them easily, might deter the entry of start-ups and small companies into the market. Moreover, the absence of IP protection of bioinformatics can hinder international cooperation. The fact that IP protections vary in jurisdictions presents a problem to bioinformatics companies in the global marketplace because they need to adapt to different jurisdictions on the eligibility of patents, data privacy, and database protection [47]. Such inconsistencies may result in patent thickets where overlapping patents in various locations make it difficult to license and possibly deter cross-border research collaborations, thus making it harder to realize the global effects of bioinformatics [48].

Patentability of Algorithms

Algorithms play a key role in data analysis in bioinformatics and allow the complex processes of DNA sequencing, protein structure prediction, and gene annotation. Patent legislation in most jurisdictions, however, considers algorithms to be abstract ideas or mathematical procedures, which are not patentable except to the extent that they exhibit a distinct, practical use. The case of Alice Corp. v. CLS Bank International [39] in the United States was a major limitation to the patentability of algorithms since it decided that abstract ideas, even when implemented by software, must include a transformative technological solution to qualify as a patent [49]. This case has posed a problem to bioinformatics pioneers who invent complicated computational algorithms that are of invaluable use to the industry, but which do not qualify to be patented because they are also algorithms. This has made most bioinformatics companies unable to patent their core technologies, and hence, they are at risk of competition and imitation.

The European patent law also has limitations on the patentability of software-related inventions, such as bioinformatics algorithms, by stating that they must address a particular technical issue [50]. Although this standard is more flexible than the U.S. one, numerous bioinformatics technologies that do not have direct technical uses beyond data processing and analysis are still not encompassed in it [51]. This is a limitation to bioinformatics firms that seek to secure proprietary algorithms which have small physical output, but their intellectual value is huge. To conclude, the current patent systems lack the support of the special requirements of bioinformatics. With the field still in its infancy, there is a threat of a lack of solid patent protection, where the innovation would be stifled, competition would be curtailed, and the innovations of bioinformatics would not be as accessible to the wider research fraternity.

3.2.3. Copyright Law in Bioinformatics

The copyright law that safeguards original expression of ideas but not the idea has been of limited use in protecting bioinformatics information, especially the genetic sequences and associated biological information [52]. Although the structural arrangement of a bioinformatics database or the particular coded software could be covered by copyright, raw data cannot be, and it is regarded as a factual component and not a creative one [53]. This restricts large curated datasets, such as genetic or proteomic data, from being very vulnerable, though the development and upkeep of these databases are very demanding in terms of resources. Database Directive of the European Union offers sui generis protection to databases, and gives exclusive rights to extraction and re-use of the database content, irrespective of the originality of the single entries [54]. This is, however, restricted to the EU and bioinformatics databases in other parts of the world, such as the United States, are not covered. In places that do not have sui generis protection, bioinformatics firms are usually at a disadvantage of protecting databases through IP rights and allowing competitors to easily copy and steal valuable information without compensating them [55]. The absence of strong IP safeguards on raw biological data, as genetic data continues to play a more important role in research and development, is a threat to the privacy of individuals and commercial investment in bioinformatics.

Copyright Protection for Databases, Sequences, and Software

Copyright in bioinformatics databases is used to protect the arrangement and choice of data, provided it is of original effort. Nevertheless, the raw genetic or proteomic sequences are not copyrightable, as the law on copyright does not apply to factual information, but to the expressive form of information. As an example, the Database Directive of the European Union provides a sui generis right, which provides database owners with exclusive rights to extract and reuse database content, whether or not original [56]. Although this has enhanced the database protections within the EU, the same protections do not exist in other areas, such as the U.S., where copyright is only applied to the structure of databases and not the data itself [57].

Effectiveness and Limitations of Copyright in Bioinformatics

The protection of software code and of database structure in bioinformatics is sufficient under copyright protection, but its restriction is considerable. Because it does not specify such functional aspects as algorithms or the factual content of databases, competitors are legally allowed to copy the raw information, provided they do so in a different format, which will reduce the value of the copyright of databases holding genetic information [58]. Thus, the use of copyright as a sole source of protection of databases may not be enough to stop the illegal use of bioinformatics data, which is where the lack of protection can be filled by other or other types of protection.

3.2.4. Trade Secrets and Bioinformatics Data Protection

Trade secrets are commonly applied in bioinformatics firms to safeguard proprietary algorithms, data and processes that are not subject to patent eligibility criteria [59]. A trade secret is not publicly disclosed as patents are, and thus, an organization can maintain the secrecy of its innovation throughout its lifetime. Trade secrets are, however, hard to keep in the cooperative and information exchange facilities of bioinformatics research [60]. Any information shared becomes no longer a trade secret, and protecting bioinformatics firms through trade secrets becomes difficult in open-science situations [61]. The teamwork of bioinformatics studies frequently implies the exchange of data to promote scientific innovations, which is incompatible with the secrecy norms required to preserve the protection of trade secrets. As an example, genetic and proteomic databases are often shared across institutions to facilitate collaborative research efforts, and it is practically impossible to hold such resources as trade secrets. The restriction makes the trade secrets a powerful IP tool that bioinformatics companies can use, since it is difficult to strike a balance between the necessity to keep the trade secret and the open access to research that facilitates collaboration in research [62].

Table 4: Case Studies of IP Disputes in Bioinformatics

Case	Issue	Court Ruling	Impact on Bioinformatics IP
Myriad Genetics v. AMP	Patentability of human genes	The Supreme Court overturned gene patents	Restricted gene patenting
Alice Corp. v. CLS Bank	Software patent eligibility	Limited abstract idea patents	Challenged bioinformatics software patents
In re BRCA1/BRCA2 Patent	Data ownership for genetic testing	Limited ownership rights	Encouraged data-sharing norms
Case	Issue	Court Ruling	Impact on Bioinformatics IP
Myriad Genetics v. AMP	Patentability of human genes	The Supreme Court overturned gene patents	Restricted gene patenting

The following table summarizes major IP controversies in bioinformatics, including decisions that limited patenting of genes, ruled on bioinformatics software and data-sharing practices. These instances have influenced the patenting of genetic information and bioinformatics tools.

Figure 2: Flowchart of Data Sharing vs. IP Protection in Bioinformatics



This flowchart depicts the decision-making process in bioinformatics between open data sharing and IP protection. It highlights the trade-offs between fostering collaboration through open data and securing competitive advantage with proprietary protection.

Figure 3: Venn Diagram of IP and Data Privacy Overlaps in Bioinformatics

The Venn diagram shows the intersection between the IP protection and the data privacy legislation in bioinformatics, with particular emphasis on genetic data privacy and secure information sharing. It brings out the specific issues of IP, including proprietary technology and data privacy legislation, which place a higher emphasis on personal data protection and consent.

Figure 4: Schematic Diagram of Bioinformatics Data Flow and IP Points of Protection



This schematic representation shows the flow of data in bioinformatics and the places where various types of IP protections, including patents, copyrights, trade secrets, and data privacy laws, are implemented at each point. It explains the way researchers incorporate IP in the entire research process, including data collection to publication.

3.3. Comparative Legal Analysis

This part of the paper is a comparison of bioinformatics protection in the United States, the European Union, and Japan in terms of intellectual property (IP). The laws on patent eligibility, database protection, and data privacy vary in each region, which poses a challenge to bioinformatics innovations. Alice Corp. v. CLS Bank case limited patenting of algorithms in the United States, where the patents had to prove a technical implementation of abstract ideas. The European Union provides patents on algorithms that address a technical issue, whereas Japan only provides patents on an algorithm when linked to an industrial application. Under the Database Directive, the EU assigns specific rights in the protection of databases.

Conversely, the U.S. is based on copyright and trade secrets, and Japan has no particular protection, but it is based on the general laws of IP, such as copyright and trade secrets. There are also major challenges in data privacy, especially when it comes to genetic data. The General Data Protection Regulation (GDPR) of the EU is a strict data privacy law that has an impact on bioinformatics IP, particularly in dealing with genetic data [63]. In the United States, data exchanged with the EU must comply with the GDPR, which makes it challenging to protect IP. The data protection laws in Japan are not as strict as the ones in the EU and therefore provide more freedom to bioinformatics innovations [64]. The present comparative analysis reveals that harmonized IP frameworks are necessary to enhance bioinformatics research so that the IP protections can have the same direction as the growing worldwide concern of data privacy and security.

Table 5: Comparative International Approaches to Bioinformatics IP Protection

Aspect	United States	European Union	Japan
Patent Eligibility for Algorithms	Limited to post-Alice case; must have technical application beyond mere ideas	Allowed if it solves a technical problem	It is only permitted if connected to an industrial application

Database Protection	No specific sui generis protection; relies on copyright and trade secrets	Protected under the Database Directive; exclusive rights over extraction and reuse	No specific database protection, copyright, or trade secrets apply
Copyright Protection	Covers software code but not underlying algorithms; limited in scope	Covers database structure, but not data itself	Similar to the U.S. and EU, it covers specific software expressions
Trade Secret Viability	Commonly used but compromised in collaborative environments	Limited by open-access data-sharing requirements	Applicable but limited in collaborative research scenarios
Data Privacy and Genetic Data	GDPR compliance is required for U.S.-EU data exchanges, complicating IP protections	GDPR enforces strict data privacy, impacting bioinformatics IP	Data protection regulations are in place, but are less strict than the GDPR ones.

The table provides a comparison of IP and data privacy laws in the U.S., EU and Japan. It demonstrates that the patents on algorithms are permitted with different limitations, and the EU demands a technical issue, while Japan concentrates on the applications of the industry. The level of protection of databases varies in different jurisdictions, with the EU providing particular protection, and the privacy of genetic data is higher in the EU under GDPR.

3.4. International Legal Instruments

International treaties and agreements play an important role in the harmonization of IP standards across states, to help in cross-border protection of bioinformatics innovations.

TRIPS Agreement

One of the most inclusive global IP contracts under the administration of the World Trade Organization is the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) [65]. It lays out the minimum requirements of IP protection that every member state has to observe, which include patents, copyrights, trademarks, and trade secrets. TRIPS will also require the member countries to reward patent protection to all inventions, even those of biotechnology and bioinformatics, therefore creating a global minimum standard of protection of IP [66]. Nevertheless, TRIPS does give room to maneuver on the part of the countries, particularly in such fields as the field of public health, which are likely to affect the manner in which bioinformatics IP is safeguarded in various jurisdictions [67]. As an example, exceptions in patent regulations can be imposed by low- and middle-income nations to make needed medicines or technologies available, which would result in possible differences in the standards of IP protection in different regions [68].

WIPO Treaties

The World Intellectual Property Organization (WIPO) manages a number of treaties to streamline and enhance the protection of IP across the world. Some of the notable treaties that have an impact on bioinformatics IP are:

- **Patent Cooperation Treaty (PCT):** The PCT simplifies the international patent registration process, where one can apply to patent the invention in more than one country in one application. It is a useful treaty in bioinformatics innovations because it offers the innovator an opportunity to protect their inventions throughout the world, as it is easier and cheaper to file a patent [16].
- **Berne Convention for the Protection of Literary and Artistic Works:** The Berne Convention is a set of standards governing copyright protection, which is applied to software and databases in bioinformatics. It

requires that the members automatically acknowledge and safeguard the copyright of works of other member countries, giving bioinformatics firms copyright security across borders [35].

- **Trade Secrets Treaty**: Although WIPO does not possess a full-fledged treaty that specifically deals with trade secrets, the organization has come up with guidelines that assist nations in coming up with national trade secret safeguards that are in line with international standards. These principles are becoming more applicable to bioinformatics as proprietary algorithms and methods are frequently considered trade secrets, which have another source of protection in the form of a patent [29].

Policy Implications and Recommendations

The bioinformatics field requires organizations to establish special legal systems and approaches to tackle the special issues in the protection of intellectual property (IP). There are a number of policy steps that are required to fit and integrate the current laws, promote innovation, and weigh the public and personal interests. The recommendations below identify the possible changes and measures for improving the IP protection in this fast-changing area.

Legal Reform

- **Update IP Laws:** The law should be revised to modernize the old IP laws and deal with the new bioinformatics developments that include algorithms and biological information. Implement sui generis data protection of databases similar to the EU Database Directive for datasets which need to be invested in.

International Cooperation

- **Harmonize Laws:** Harmonize IP protection on an international basis under treaties or WIPO-led frameworks such as TRIPS in order to promote uniformity and cross-border bioinformatics cooperation.

Encouraging Innovation

- **Incentives and Support:** Introduce tax credits, grants and funds to bioinformatics research and development, like projects in genomic data analysis. Open-access databases, which are publicly funded, can facilitate cooperation and allow the development of proprietary tools.

Balancing Interests

- **Access vs. Protection:** Combine open-access models with proprietary IP rights for innovation while maintaining accessibility. Completely apply compulsory licensing in the needs of public health, and fair compensation is to be given to the IP holders.

Awareness and Training

- **Educate Stakeholders:** The stakeholders that will be educated include the researchers, legal professionals, and policymakers on bioinformatics IP strategies and ethical practices- close the gap between scientific and legal fields to make informed policy decisions.

IP Challenges in AI-Driven Bioinformatics:

Artificial Intelligence (AI) is transforming bioinformatics because it allows analyzing complicated biological data quickly, including genomic sequences and protein structures. Nevertheless, AI systems present challenges related to IP in a special way. As an example, the AI-generated innovations (e.g., a novel drug candidate or a biomarker discovered in the course of a machine learning algorithm) are not explicitly mentioned in the patent eligibility criteria. Existing IP regulations usually presuppose human inventorship, which makes it difficult to protect outputs that were obtained autonomously by AI systems. There is a need to reform the laws to target the issue of ownership attribution and patentability of AI-driven bioinformatics findings.

Bioinformatics is the convergence of biology, computer science and information technology that analyzes and interprets complex biological information, which has contributed to new developments in genomics, proteomics, drug discovery and personalized medicine. Nonetheless, the discipline is marked with serious intellectual property (IP) issues because it uses algorithms, databases, and collaborative studies. Bioinformatics innovations are hard to fit into the patent laws, and in many cases, algorithms and software are not applicable. Copyright does not provide much protection to databases and software structures, but not raw data or functional algorithms. Although trade secrets are precious, they are hard to keep in a teamwork setup. The international differences in IP protections, as witnessed in the U.S., EU and Japan, make such challenges worse, hindering innovations and cross-national cooperation. Standardized systems of law, innovation stimulation, open source, and stakeholder training are paramount in resolving these gaps. Besides, the rise of AI in bioinformatics presents new IP issues, especially in the context of the patentability of the AI-generated products, which would require additional legal reforms to facilitate sustainable innovation in the revolutionary sector.

4. CONCLUSION

This paper indicates that there are apparent constraints in the current intellectual property systems in the application of bioinformatics. The nature of the bioinformatics outputs is not in tandem with the current regimes like patents, copyright and trade secrets. The patent law limits the protection to algorithms and software unless the technical requirements are highly met, and this limits protection to basic computing devices. Copyrights only cover expression, which does not include uncooked information such as genetic sequences and databases, which are the backbone of bioinformatics research. The basis of trade secret protection relies on confidentiality, which is incompatible with the principles of collaboration and data sharing that are typical of the given sphere. These institutional loopholes decrease the predictability of the law and influence the incentives to innovate, invest, and commercialize. The discussion of the international frameworks shows that there is a difference in jurisdiction, resulting in inconsistency in the protection of bioinformatics assets. The differences in the standards of patent eligibility and the protection regime in databases impact the cross-border research and data exchange. Such inconsistency poses obstacles to international cooperation and poses a legal risk to researchers and institutions that deal with common biological data. Simultaneously, the paper points to the current conflict between the necessity to maintain intellectual property and the necessity to preserve open access to scientific information, which is the key to advancement in the sphere of genomics and other areas. The results prove the fact that bioinformatics is located at the border of data science and life sciences since conventional intellectual property types demonstrate their boundaries. The bioinformatics innovation has not yet been completely accommodated within legal systems because of the scale, complexity, and collaborative aspect of bioinformatics innovation. In order to ensure long-term scientific and technological advancement, a balanced system that would allow the protection and accessibility is required. Context-specific and strengthened legal approaches will be very instrumental in determining the future of bioinformatics and its role in healthcare, biotechnology, and research.

References

[1]. Mount, D. W. (2004). Bioinformatics: Sequence and Genome Analysis. Cold Spring Harbor Laboratory Press.

[2]. Pevsner Bioinformatics and Functional Genomics. John Wiley & Sons., J. (2015).

[3]. Kanehisa, M., & Goto, S. (2000). KEGG: kyoto encyclopedia of genes and genomes. Nucleic acids research, 28(1), 27-30.

[4]. Durbin, R., Eddy, S. R., Krogh, A., & Mitchison, G. (1998). Biological sequence analysis: probabilistic models of proteins and nucleic acids. Cambridge university press.

[5]. Zhang, Z., Schwartz, S., Wagner, L., & Miller, W. (2000). A greedy algorithm for aligning DNA sequences. Journal of Computational biology, 7(1-2), 203-214.

[6]. International Cancer Genome Consortium. (2010). International network of cancer genome projects. Nature, 464(7291), 993.

[7]. Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P. A., Harshman, K., Tavtigian, S., ... & Skolnick, M. H. (1994). A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science, 266(5182), 66-71.

[8]. Ashley, E. A. (2015). The precision medicine initiative: a new national effort. Jama, 313(21), 2119-2120.

[9]. Hanash, S. M., Pitteri, S. J., & Faca, V. M. (2008). Mining the plasma proteome for cancer biomarkers. Nature, 452(7187), 571-579.

[10]. Keasling, J. D. (2010). Manufacturing molecules through metabolic engineering. Science, 330(6009), 1355-1358.

[11]. Tester, M., & Langridge, P. (2010). Breeding technologies to increase crop production in a changing world. Science, 327(5967), 818-822.

[12]. WIPO., Available at: https://www.wipo.int/publications/en/details.jsp?id=4080

[13]. Eisenberg, R. S. (2006). Patents and data-sharing in public science. Industrial and Corporate Change, 15(6), 1013-1031.

[14]. Scheibner, J. K. (2019). Open source bioinformatics: the intersection between formal intellectual property laws and user generated laws in the scientific research commons (Doctoral dissertation, University Of Tasmania).

[15]. Casaletto, J. (2023). Overcoming data privacy and data gravity challenges in bioinformatics research. University of California, Santa Cruz.

[16]. Cohen, J. E., & Lemley, M. A. (2001). Patent scope and innovation in the software industry. Calif. L. Rev., 89, 1.

[17]. Derclaye, E. (2008). The legal protection of databases: a comparative analysis. Edward Elgar Publishing.

[18]. Gopalan, R. (2009). Bioinformatics: scope of intellectual property protection. Journal of Intellectual Property Rights, 14, 316-322.

[19]. Bagley, M. A. (2014). Patent Barbarians at the Gate: The Who, What, When, Where, Why & How of US Patent Subject Matter Eligibility Disputes.

[20]. Singh, K. K., & Singh, K. K. (2015). Intellectual Property Protection to Bioinformatics and Genomic Databases and Open Source Analogy to Biotechnology. In Biotechnology and Intellectual Property Rights: Legal and Social Implications (pp. 169-193).

[21]. Atsar, A. (2017). Legal protection of invention in the field of bioinformatics in Indonesia and Singapore. In International Conference on Law, Governance and Globalization 2017 (ICLGG 2017) (pp. 1-11). Atlantis Press.

[22]. Kumar, A. (2019). Bioinformatics: Nuances in Granting IP Protection. In Intellectual Property Issues in Microbiology (pp. 103-117).

[23]. Egbunike, C. C. (2021). The Human Patent: What Intellectual Property Rights Does an Individual Have in Their Own Genetic Material, and What Are the Global Biosecurity Implications? Journal of Biosecurity, Biosafety, and Biodefense Law, 12(1), 25-48.

[24]. Nath, A., & Chakravarty, G. (2023). Intellectual Property in Human Genomics in India. In Doctoral Symposium on Human Centered Computing (pp. 54-64). Singapore: Springer Nature Singapore.
[25]. Patel, M. B., Patel, J., Patel, D., Prajapati, P., & Prajapati, J. (2023). Basic Ethical Issues in Bioinformatics and Chemoinformatics. In Ethical Issues in AI for Bioinformatics and Chemoinformatics (pp. 12-38). CRC Press.
[26]. Gomase, V., Kemkar, K., & Potnis, V. (2024). Intellectual Property Rights: Protection of Biotechnological Inventions in India. Recent Patents on Biotechnology, 18(2), 128-143.
[27]. Alice Corp. v. CLS Bank International, 573 U.S. 208 (2014).
[28]. Mayo Collaborative Services v. Prometheus Laboratories, Inc., 566 U.S. 66 (2012).
[29]. Diamond v. Diehr, 450 U.S. 175 (1981).
[30]. Assoc. for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013)
[31]. Bernier, A., Busse, C., & Bubela, T. M. (2023). Public biological databases and the Sui Generis database right. IIC International Review of Intellectual Property and Competition Law, 54(9), 1316.
[32]. Matveev, A., & Martyanova, E. (2022). Patentability of Computer Program Algorithms in the G20 States. BRICS Law Journal, 9(3), 144-173.
[33]. Lesk, A. M. (2019). Introduction to bioinformatics. Oxford university press.
[34]. Senior, A. W., Evans, R., Jumper, J., Kirkpatrick, J., Sifre, L., Green, T., ... & Hassabis, D. (2020). Improved protein structure prediction using potentials from deep learning. Nature, 577(7792), 706-710.
[35]. Adelusi, T. I., Oyedele, A. Q. K., Boyenle, I. D., Ogunlana, A. T., Adeyemi, R. O., Ukachi, C. D., & Abdul-Hammed, M. (2022). Molecular modeling in drug discovery. Informatics in Medicine Unlocked, 29, 100880.
[36]. Clark, A. J., & Lillard Jr, J. W. (2024). A Comprehensive Review of Bioinformatics Tools for Genomic Biomarker Discovery Driving Precision Oncology. Genes, 15(8), 1036.
[37]. Ashley, E. A. (2016). Towards precision medicine. Nature Reviews Genetics, 17(9), 507-522.
[38]. Collins, F. S., & Varmus, H. (2015). A new initiative on precision medicine. New England journal of medicine, 372(9), 793-795.
[39]. Cameron, D. E., Bashor, C. J., & Collins, J. J. (2014). A brief history of synthetic biology. Nature Reviews Microbiology, 12(5), 381-390.
[40]. Einerhand, M. P., & Van Melle, J. (2004). Patenting of Inventions in the Field of Bioinformatics. In The New Avenues in Bioinformatics (pp. 239-254). Dordrecht: Springer Netherlands.
[41]. Vishnubhakat, S., & Rai, A. K. (2022). BIOINFORMATICS AT THE PATENT OFFICE. In Bioinformatics, Medical Informatics and the Law (pp. 120-132). Edward Elgar Publishing.
[42]. Taylor, D. O. (2016). Amending Patent Eligibility. UCDL Rev., 50, 2149.
[43]. de Lisa, I., & de Lisa, I. (2020). The Patent Eligibility of Synthetic Biology Inventions. The Patentability of Synthetic Biology Inventions: New Technology, Same Patentability Issues?, 91-226.
[44]. Einerhand, M. P., & Van Melle, J. (2004). Patenting of Inventions in the Field of Bioinformatics. In The New Avenues in Bioinformatics (pp. 239-254). Dordrecht: Springer Netherlands.
[45]. Harvey, M., & McMeekin, A. (2002). UK Bioinformatics: current landscapes and future horizons. London, UK: Department of Trade and Industry.
[46]. Mago, N., & Deshpande, N. (2018). Patent data for comparative study: case study of top aspirants in bioinformatics industry. International Journal of Innovation, 6(1), 33-39.
[47]. Poddar, A., & Rao, S. R. (2024). Evolving intellectual property landscape for AI-driven innovations in the biomedical sector: opportunities in stable IP regime for shared success. Frontiers in Artificial Intelligence, 7, 1372161.
[48]. Bertoni, A. (2013). Open Source Models in Biomedicine: Workable Complementary Flexibilities Within the Patent System. Wake Forest J. Bus. & Intell. Prop. L., 14, 126.
[49]. Hsiao, J. I. (2019). Patent eligibility of predictive algorithm in second generation personalized medicine. SMU Sci. & Tech. L. Rev., 22, 23.
[50]. European Patent Office, 2019, Available at : https://www.epo.org/en/publication-content/guidelines-examination-european-patent-office-2019

[51]. Derclaye, E. (2007). Database sui generis right: the need to take the public's right to information and freedom of expression into account. New directions in copyright law, 5, 3.
[52]. Wilson, S. R. (2003). Copyright protection for DNA sequences: can the biotech industry harmonize science with song. Jurimetrics, 44, 409.
[53]. Godt, C. (2024). Information property: navigator principles for the private–public conundrum between digital data and immaterial property (IP). In Research Handbook on European Property Law (pp. 219-246). Edward Elgar Publishing.
[54]. Trosow, S. E. (2004). Sui generis database legislation: A critical analysis. Yale JL & Tech., 7, 534.
[55]. Smith, M. (2010). A comparison of the legal protection of databases in the United States and EU: Implications for scientific research. Available at SSRN 1613451.
[56]. Senftleben, M. R. (2022). Study on EU copyright and related rights and access to and reuse of data. Publications Office of the European Union.
[57]. Derclaye, E. (2008). The legal protection of databases: a comparative analysis. Edward Elgar Publishing.
[58]. D'Souza, S. (2003). Gene meets machine: intellectual property issues in bioinformatics. Health L. Rev., 12, 34.
[59]. McBride, M. S. (2002). Bioinformatics and intellectual property protection. Berkeley Tech. LJ, 17, 1331.
[60]. Kumar, D., Gupta, S., & Parmar, P. Legal Frameworks for Data Privacy and Ownership in Metagenomics. In Genomic Intelligence (pp. 291-305). CRC Press.
[61]. Klunker, I., & Richter, H. (2022). Digital Sequence Information between Benefit-Sharing and Open Data. JL & Biosciences, 9, 1.
[62]. Liddicoat, J., & Liddell, K. (2017). Open Innovation with Large Bioresources: Goals, Challenges and Proposals. University of Cambridge Faculty of Law Research Paper, (6).
[63]. Madej, M., Karpiński, P., Akopyan, H., Witt, M., & Sąsiadek, M. M. (2023). Genetic data protection as an indispensable element of genomic medicine development. Polskie Archiwum Medycyny Wewnętrznej, 133(2).
[64]. Pesqueira, A., de Bem Machado, A., & Bolog, S. (2024). Exploring the impact of EU tendering operations on future AI governance and standards in pharmaceuticals. Computers & Industrial Engineering, 110655.
[65]. Li, X. (2010). The Agreement on Trade-Related Aspects of Intellectual Property Rights Flexibilities on Intellectual Property Enforcement: The World Trade Organization Panel Interpretation of China-Intellectual Property Enforcement of Criminal Measures and Its Implications. The Journal of World Intellectual Property, 13(5), 639-659.
[66]. Chiarolla, C. (2014). Intellectual property rights and benefit sharing from marine genetic resources in areas beyond national jurisdiction: current discussions and regulatory options. Queen Mary Journal of Intellectual Property, 4(3), 171-194.
[67]. Ho, C. M. (2005). Biopiracy and beyond: a consideration of socio-cultural conflicts with global patent policies. U. Mich. JL Reform, 39, 433.
[68]. Stevens, H., & Huys, I. (2017). Innovative approaches to increase access to medicines in developing countries. Frontiers in medicine, 4, 218.

Cite this Article:

***Manindra Singh Hanspal*, " *BIOINFORMATICS AND INTELLECTUAL PROPERTY PROTECTION: AN OVERVIEW*",** *Ved International Journal of Arts, Commerce and Technology (VIJACT), ISSN: 3139-1656 (Online), Volume 2, Issue 3, pp. 01-21, March 2026.*
Journal URL: https://vijact.com
***DOI:** https://doi.org/10.65785/vijact.v1i2.20*